Research programme: Fas receptor antagonists - ONL Therapeutics

Drug Profile

Research programme: Fas receptor antagonists - ONL Therapeutics

Alternative Names: Met12; ONL 1204; ONL101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ONL Therapeutics
  • Class Eye disorder therapies; Peptides; Small molecules
  • Mechanism of Action CD95 antigen inhibitors; Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal detachment
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • No development reported Retinal detachment

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinal detachment in USA (Intravitreous, Injection)
  • 11 Feb 2016 ONL 1204 receives Orphan Drug status for Retinal detachment in USA
  • 15 Jun 2015 ONL Therapeutics plans a clinical trial for Retinal detachment in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top